Radequinil
Chemical compound
- None
- 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
- 219846-31-8
- 22714308
- 11584471
- 2G222T03EY
- DTXSID60944577
- Interactive image
- COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4
InChI
- InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
- Key:JQOFKKWHXGQABB-UHFFFAOYSA-N
Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]
See also
- GABAA receptor negative allosteric modulator
- GABAA receptor § Ligands
References
- ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. doi:10.2174/1876523800801010019.
- ^ Pogacić V, Herrling P (2007). "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases. 4 (6): 443–86. doi:10.1159/000107705. PMID 17934328.
- v
- t
- e
GABA receptor modulators
GABABTooltip γ-Aminobutyric acid B receptor |
|
---|
- See also
- Receptor/signaling modulators
- GABAA receptor positive modulators
- GABA metabolism/transport modulators
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e